LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Rapid Phenotypic Antibiotic Susceptibility Profiling of Clinical

    Hefetz, Idan / Bardenstein, Rita / Rotem, Shahar / Zaide, Galia / Bilinsky, Gal / Shifman, Ohad / Zimhony, Oren / Aloni-Grinstein, Ronit

    Antibiotics (Basel, Switzerland)

    2024  Volume 13, Issue 3

    Abstract: Bloodstream infections (BSI) are defined by the presence of viable bacteria or fungi, accompanied by systemic signs of infection. Choosing empirical therapy based solely on patient risk factors and prior antibiotic susceptibility test (AST) may lead to ... ...

    Abstract Bloodstream infections (BSI) are defined by the presence of viable bacteria or fungi, accompanied by systemic signs of infection. Choosing empirical therapy based solely on patient risk factors and prior antibiotic susceptibility test (AST) may lead to either ineffective treatment or unnecessarily broad-spectrum antibiotic exposure. In general, Clinical & Laboratory Standards Institute guideline-approved ASTs have a turnaround time of 48-72 h from sample to answer, a period that may result in a critical delay in the appropriate selection of therapy. Therefore, reducing the time required for AST is highly advantageous. We have previously shown that our novel rapid AST method, MAPt (Micro-Agar-PCR-test), accurately identifies susceptibility profiles for spiked bioterrorism agents like
    Language English
    Publishing date 2024-02-29
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics13030231
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A reversible mutation in a genomic hotspot saves bacterial swarms from extinction.

    Hefetz, Idan / Israeli, Ofir / Bilinsky, Gal / Plaschkes, Inbar / Hazkani-Covo, Einat / Hayouka, Zvi / Lampert, Adam / Helman, Yael

    iScience

    2023  Volume 26, Issue 2, Page(s) 106043

    Abstract: Microbial adaptation to changing environmental conditions is frequently mediated by hypermutable sequences. Here we demonstrate that such a hypermutable hotspot within a gene encoding a flagellar unit ... ...

    Abstract Microbial adaptation to changing environmental conditions is frequently mediated by hypermutable sequences. Here we demonstrate that such a hypermutable hotspot within a gene encoding a flagellar unit of
    Language English
    Publishing date 2023-01-25
    Publishing country United States
    Document type Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2023.106043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel

    Nechooshtan, Ram / Ehrlich, Sharon / Vitikainen, Marika / Makovitzki, Arik / Dor, Eyal / Marcus, Hadar / Hefetz, Idan / Pitel, Shani / Wiebe, Marilyn / Huuskonen, Anne / Cherry, Lilach / Lupu, Edith / Sapir, Yehuda / Holtzman, Tzvi / Aftalion, Moshe / Gur, David / Tamir, Hadas / Yahalom-Ronen, Yfat / Ramot, Yuval /
    Kronfeld, Noam / Zarling, David / Vallerga, Anne / Tchelet, Ronen / Nyska, Abraham / Saloheimo, Markku / Emalfarb, Mark / Ophir, Yakir

    Vaccines

    2022  Volume 10, Issue 12

    Abstract: SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and virulence. The original and mutant viruses escape host innate (Interferon) immunity and adaptive (Antibody) immunity, emphasizing unmet needs for high-yield, commercial- ... ...

    Abstract SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and virulence. The original and mutant viruses escape host innate (Interferon) immunity and adaptive (Antibody) immunity, emphasizing unmet needs for high-yield, commercial-scale manufacturing to produce inexpensive vaccines/boosters for global/equitable distribution. We developed DYAI-100A85, a SARS-CoV-2 spike receptor binding domain (RBD) subunit antigen vaccine expressed in genetically modified thermophilic filamentous fungus,
    Language English
    Publishing date 2022-12-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines10122119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate

    Makovitzki, Arik / Lerer, Elad / Kafri, Yaron / Adar, Yaakov / Cherry, Lilach / Lupu, Edith / Monash, Arik / Levy, Rona / Israeli, Ofir / Dor, Eyal / Epstein, Eyal / Levin, Lilach / Toister, Einat / Hefetz, Idan / Hazan, Ophir / Simon, Irit / Tal, Arnon / Girshengorn, Meni / Tzadok, Hanan /
    Rosen, Osnat / Oren, Ziv

    Vaccine. 2021 Nov. 26, v. 39, no. 48

    2021  

    Abstract: rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal ... ...

    Abstract rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal models. Bringing rVSV-S to clinical trials required the development of a scalable downstream process for the production of rVSV-S that can meet regulatory guidelines. The objective of this study was the development of the first downstream unit operations for cell-culture-derived rVSV-S, namely, the removal of nucleic acid contamination, the clarification and concentration of viral harvested supernatant, and buffer exchange. Retaining the infectivity of the rVSV-S during the downstream process was challenged by the shear sensitivity of the enveloped rVSV-S and its membrane protruding spike protein. Through a series of screening experiments, we evaluated and established the required endonuclease treatment conditions, filter train composition, and hollow fiber-tangential flow filtration parameters to remove large particles, reduce the load of impurities, and concentrate and exchange the buffer while retaining rVSV-S infectivity. The combined effect of the first unit operations on viral recovery and the removal of critical impurities was examined during scale-up experiments. Overall, approximately 40% of viral recovery was obtained and the regulatory requirements of less than 10 ng host cell DNA per dose were met. However, while 86–97% of the host cell proteins were removed, the regulatory acceptable HCP levels were not achieved, requiring subsequent purification and polishing steps. The results we obtained during the scale-up experiments were similar to those obtained during the screening experiments, indicating the scalability of the process. The findings of this study set the foundation for the development of a complete downstream manufacturing process, requiring subsequent purification and polishing unit operations for clinical preparations of rVSV-S.
    Keywords COVID-19 infection ; DNA ; Severe acute respiratory syndrome coronavirus 2 ; animals ; filtration ; pathogenicity ; viral vaccines
    Language English
    Dates of publication 2021-1126
    Size p. 7044-7051.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2021.10.045
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.

    Makovitzki, Arik / Lerer, Elad / Kafri, Yaron / Adar, Yaakov / Cherry, Lilach / Lupu, Edith / Monash, Arik / Levy, Rona / Israeli, Ofir / Dor, Eyal / Epstein, Eyal / Levin, Lilach / Toister, Einat / Hefetz, Idan / Hazan, Ophir / Simon, Irit / Tal, Arnon / Girshengorn, Meni / Tzadok, Hanan /
    Rosen, Osnat / Oren, Ziv

    Vaccine

    2021  Volume 39, Issue 48, Page(s) 7044–7051

    Abstract: rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal ... ...

    Abstract rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against SARS-CoV-2 infection in animal models. Bringing rVSV-S to clinical trials required the development of a scalable downstream process for the production of rVSV-S that can meet regulatory guidelines. The objective of this study was the development of the first downstream unit operations for cell-culture-derived rVSV-S, namely, the removal of nucleic acid contamination, the clarification and concentration of viral harvested supernatant, and buffer exchange. Retaining the infectivity of the rVSV-S during the downstream process was challenged by the shear sensitivity of the enveloped rVSV-S and its membrane protruding spike protein. Through a series of screening experiments, we evaluated and established the required endonuclease treatment conditions, filter train composition, and hollow fiber-tangential flow filtration parameters to remove large particles, reduce the load of impurities, and concentrate and exchange the buffer while retaining rVSV-S infectivity. The combined effect of the first unit operations on viral recovery and the removal of critical impurities was examined during scale-up experiments. Overall, approximately 40% of viral recovery was obtained and the regulatory requirements of less than 10 ng host cell DNA per dose were met. However, while 86-97% of the host cell proteins were removed, the regulatory acceptable HCP levels were not achieved, requiring subsequent purification and polishing steps. The results we obtained during the scale-up experiments were similar to those obtained during the screening experiments, indicating the scalability of the process. The findings of this study set the foundation for the development of a complete downstream manufacturing process, requiring subsequent purification and polishing unit operations for clinical preparations of rVSV-S.
    MeSH term(s) Animals ; Antibodies, Neutralizing ; COVID-19 ; COVID-19 Vaccines ; Humans ; Pandemics ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
    Chemical Substances Antibodies, Neutralizing ; COVID-19 Vaccines ; Spike Glycoprotein, Coronavirus
    Language English
    Publishing date 2021-10-22
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2021.10.045
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top